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Abstract
Background: Despite their widespread use the effects of taking benzodiazepines and non-benzodiazepine hypnotics during
pregnancy on the risk of major congenital anomaly (MCA) are uncertain. The objectives were to estimate absolute and
relative risks of MCAs in children exposed to specific anxiolytic and hypnotic drugs taken in the first trimester of pregnancy,
compared with children of mothers with depression and/or anxiety but not treated with medication and children of
mothers without diagnosed mental illness during pregnancy.
Methods: We identified singleton children born to women aged 15–45 years between 1990 and 2010 from a large United
Kingdom primary care database. We calculated absolute risks of MCAs for children with first trimester exposures of different
anxiolytic and hypnotic drugs and used logistic regression with a generalised estimating equation to compare risks adjusted
for year of childbirth, maternal age, smoking, body mass index, and socioeconomic status.
Results: Overall MCA prevalence was 2.7% in 1,159 children of mothers prescribed diazepam, 2.9% in 379 children with
temazepam, 2.5% in 406 children with zopiclone, and 2.7% in 19,193 children whose mothers had diagnosed depression
and/or anxiety but no first trimester drug exposures. When compared with 2.7% in 351,785 children with no diagnosed
depression/anxiety nor medication use, the adjusted odds ratios were 1.02 (99% confidence interval 0.63–1.64) for
diazepam, 1.07 (0.49–2.37) for temazepam, 0.96 (0.42–2.20) for zopiclone and 1.27 (0.43–3.75) for other anxiolytic/hypnotic
drugs and 1.01 (0.90–1.14) for un-medicated depression/anxiety. Risks of system-specific MCAs were generally similar in
children exposed and not exposed to such medications.
Conclusions: We found no evidence for an increase in MCAs in children exposed to benzodiazepines and non-
benzodiazepine hypnotics in the first trimester of pregnancy. These findings suggest that prescription of these drugs during
early pregnancy may be safe in terms of MCA risk, but findings from other studies are required before safety can be
confirmed.
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Introduction
Mental illness is among the leading causes of disability in the
United Kingdom (UK) [1]. Compared with men, women are more
likely to develop common mental disorders such as depression and
anxiety [2], which often require drug treatment. About 3% of
women are prescribed anxiolytics, hypnotics, or antidepressants
around early pregnancy in the UK [3], a similar level to those in
other countries [4]. Since the Thalidomide scandal [5], the
potential for teratogenic effects of drugs has been a pressing
concern for all women of childbearing age and prescribers. Due to
their widespread use there has rightly been a research focus on
maternal perinatal mental health [6] and its potential effects on
children born to women taking antidepressants, mood stabilisers
and antipsychotic drugs [7]. By contrast, research into anxiolytic
and hypnotic drugs, which are commonly prescribed in association
with anxiety symptoms is severely lacking in both quantity and
quality [8]. Very few studies have examined the effect of individual
drugs or assessed the impacts of underlying health conditions and
concurrent medications [8].
A 2011 meta-analysis [9] showed no association between
congenital anomalies overall and benzodiazepine exposure in
pregnancy, however it was not a systematic review with any formal
assessment of the quality of included studies. In this analysis there
was marked heterogeneity between studies, the results were mostly
driven by two studies [10,11], and different abnormalities were
PLOS ONE | www.plosone.org 1 June 2014 | Volume 9 | Issue 6 | e100996
included in each. Previous studies have seldom distinguished
between benzodiazepines and non-benzodiazepine hypnotics (i.e.
zopiclone, zaleplone and zolpidem), which differ in chemical
structure. A population-based study from Sweden published in the
same year [12] showed little evidence for the teratogenicity of non-
benzodiazepine hypnotics, although they had previously [10]
found a 1.4-fold increased risk of major congenital anomalies
(MCAs) associated with antenatal exposure to benzodiazepines.
Evidence for system-specific congenital anomalies is even more
limited. Early case-control studies reported increased risks of facial
clefts with benzodiazepines [13,14], which have not been found in
more recent research [15–17]. Only four studies so far have been
conducted to investigate the risk of heart anomalies and have not
consistently shown increased risks [11,18–20]. In addition, a study
from British Columbia [11] highlighted the combined effect of
taking both antidepressants and benzodiazepines and suggested
that such dual drug exposure, rather than benzodiazepines alone,
was associated with an increased risk of congenital heart
anomalies. Such concurrent exposure is common and may not
have been accounted for in many other studies.
We have therefore conducted the first UK population-based
study using routinely-collected primary care data to investigate
whether first trimester exposure to benzodiazepine anxiolytics/
hypnotics and non-benzodiazepine hypnotics without concurrent
antidepressant exposure increases the risk of MCAs. We estimated
such risks for system-specific congenital anomalies and the
comparative risks among children born to women with depression
or anxiety but with no first trimester psychotropic medication.
Methods
Ethics Statement
All data are anonymised, such that individual patients as well as
the name and specific location of general practices cannot be
identified by researchers. Ethical approval for this study was
obtained from the Medical Research Ethics Committee (admin-
istered and approved by the National Health Service South East
Research Ethics Committee) REC reference 04/MRE01/9.
Study population
We used a pregnancy cohort study design which included all
singleton live births for women aged 15–45 years between 1990
and 2010 from The Health Improvement Network (THIN), where
anonymised children’s and mothers’ medical records were linked
to provide prospectively recorded information before, during and
after pregnancy. THIN is a nationally representative database of
computerised longitudinal general practice records of prospective-
ly-collected health information across the UK. The UK’s National
Health Service (NHS) is tax-payer funded and provides access to
all basic health care free at source including essential drug
prescriptions at a minimal charge. As part of the NHS, general
practice (primary health care units) is responsible for overseeing
patients’ medical care which includes coordination of their health
care from hospital or other secondary care services and is the first
point of contact for non-emergency access to almost all national
health care services. These data are therefore primarily collected
and recorded for the purpose of routine management of patient
health care in the UK NHS general practice setting, rather than
for research purposes. The version of THIN used for the purpose
of this study contained records from 495 general practices
throughout the UK, covering 5% of the total UK population.
THIN contains valid medical diagnoses, events, symptoms and
drug prescriptions and is widely used for pharmacoepidemiological
studies [21]. Prescriptions are automatically entered at the point of
issue on the database such that error in their measurement will be
minimal. Whilst medications can also be prescribed in hospital, the
vast majority are prescribed via the patient’s general practice, in
particular if they are repeat prescriptions. Since treatment for
anxiety and depression is almost entirely managed in general
practice, it is unlikely that the medications assessed in this study
will be prescribed in hospital and none are available without a
doctor’s prescription in the UK. Furthermore, during pregnancy
women receive free prescriptions via their general practice so it is
unlikely that we are missing prescriptions.
We excluded women with serious mental illness (i.e. bipolar
disorder, schizophrenia and other related psychotic disorders) and
women with epilepsy diagnoses or with prescriptions of antiepi-
leptic drugs in pregnancy (4,739 pregnancies/1.2% of the total
population) since previous literature has shown increases of
congenital anomalies in children born to women treated for such
conditions [22–24].
Outcome definitions
We extracted all diagnostic recordings of MCAs (excluding
genetic anomalies and anomalies attributed to known teratogens,
e.g. anomalies due to maternal infections and fetal alcohol
syndrome) from the children’s general practice records and
classified these into system-specific groups by using Read codes
corresponding to the European Surveillance of Congenital
Anomalies classification [25], which is based on the International
Classification of Disease (ICD-10) [26]. The recording of MCAs
among live births in THIN have shown to be highly comparable to
UK national registry data that contribute the EUROCAT [26].
Furthermore, the recording of MCAs in general practice data have
shown to have good specificity when validated against medical
notes [27–30]. Routine general practice data has also been shown
to be a useful source to monitor the outcomes of pregnancies
exposed to common environmental and medical teratogens
[31,32].
Exposure definitions
We identified all benzodiazepine drugs (diazepam, alprazolam,
chlordiazepoxide hydrochloride, lorazepam, oxazepam, nitraze-
pam, flurazepam, loprazolam, lormetazepam, temazepam, clo-
nazepam, clobazam and triazolam) and non-benzodiazepine
hypnotics (zopiclone, zaleplone and zolpidem) prescribed in UK
primary care. In the UK, these drugs are not available as over the
counter drugs and can only be issued with a prescription from a
health care professional. Antenatal exposure to these drugs during
the first trimester of pregnancy was defined according to the
presence or absence of a relevant drug prescription in women’s
primary care electronic health records from four weeks before the
estimated onset of the last menstrual period up to 12 weeks after so
as to include drug prescriptions received immediately before
pregnancy and potentially used during early pregnancy. Dates of
onset of the last menstrual period were estimated based on a range
of recordings of information related to women’s pregnancy,
delivery and gestational age of their children, and where no
information was available, live births were assumed to take place
at 40 weeks.
Nearly 90% of children whose mothers were prescribed such
drugs in this period (2,904 out of 3,218) were exposed to
diazepam, temazepam or zopiclone. For the remaining 314
children exposed to benzodiazepines and non-benzodiazepine
hypnotics other than these three we had very few exposed cases to
examine each drug separately and therefore grouped them
together. In addition, diagnostic recordings of depression and
anxiety (including generalised anxiety disorder, panic attacks,
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insomnia and other anxiety related disorder) in the year before
pregnancy or during pregnancy were also identified from women’s
medical records. The prevalence estimates of maternal depression
and anxiety in and around pregnancy in THIN are similar to
studies using standardised clinical interviewing schedules [33].
First-trimester exposure to all antidepressants, including tricyclic
antidepressants, selective serotonin reuptake inhibitors (SSRIs) and
other antidepressants in the British National Formulary 4.3 [34]
were also extracted from women’s medical records. Since we
primarily aimed to assess the MCA risk for exposure to
benzodiazepines and non-benzodiazepine hypnotics with/without
concurrent exposure to antidepressants, children born to women
with prescriptions of an antidepressant but no anxiolytic/hypnotic
drugs in the first trimester were excluded from the study (3.2% of
the total population; 12,399 pregnancies). Therefore, based on
mothers’ exposure status, we classified children into 10 antenatal
exposure groups: 1) mothers with no diagnoses of depression or
anxiety (the baseline group), 2) mothers with diagnosed depression
or anxiety in the year before pregnancy or during pregnancy but
without anxiolytic, hypnotic or antidepressant drugs deemed
above as first trimester exposures, 3–6) mothers prescribed
diazepam, temazepam, zopiclone or other anxiolytic/hypnotic
drugs without concurrent prescriptions of antidepressants, 7–10)
mothers prescribed diazepam, temazepam, zopiclone or other
anxiolytic/hypnotic drugs with co-prescriptions for antidepressants
in the first trimester. Children of mothers exposed to more than
one type of anxiolytic/hypnotic drugs were included in multiple
groups.
Covariates
For each pregnancy, we also extracted the year of the child’s
birth, maternal age at childbirth and socioeconomic status as
measured by quintiles of the Townsend Index of Deprivation [35].
In addition, we extracted the most recent maternal smoking status
before delivery and used a previously validated algorithm to
classify women’s smoking status as never smoking, ex-smoking,
and current smoking [36,37]. We also extracted the most recent
maternal body mass index (BMI) measurement before pregnancy
and classified as normal, underweight, overweight and obese
according to the WHO classification [38].
Statistical Analysis
To estimate the disease burden of all MCAs and across 14
system-specific groups we calculated absolute risks (per 10,000 live
births) for each antenatal exposure group. Multiple logistic
regression with generalised estimating equation modelling [39],
to account for potential clustering effects of children born to the
same woman in consecutive pregnancies, was used to estimate
odds ratios (ORs) with 99% confidence intervals (CIs) for the
associations of any MCA (and the three most prevalent system-
specific groups: heart, limbs and genital system) with each
exposure group. We adjusted the results for the year of the child’s
birth, maternal age at childbirth, socioeconomic status, smoking
and BMI. Children of mothers with missing information on
smoking or BMI were included in separate categories in the
multivariate analysis. The same analyses were repeated using
children of women with un-medicated depression/anxiety (group
2) as the baseline group.
Table 1. Maternal characteristic of children with and without major congenital anomalies.
All children Children without MCAs Children with MCAs
N=374,196 n=364,214 n=9,982 [2.7%]
n % n % n %
Maternal age at the end of pregnancy, years (Median, IQR) 29 25–33 29 25–33 29 25–33
Townsend deprivation index
1 (Least deprived) 90,671 24.2 88,200 24.2 2,471 24.8
2 71,478 19.1 69,596 19.1 1,882 18.9
3 72,020 19.2 70,071 19.2 1,949 19.5
4 67,115 17.9 65,360 17.9 1,755 17.6
5 (Most deprived) 49,797 13.3 48,438 13.3 1,359 13.6
Missing 23,115 6.2 22,549 6.2 566 5.7
Maternal smoking status
Never 101,006 27.0 98,465 27.0 2,541 25.5
Current smoker 52,348 14.0 51,000 14.0 1,348 13.5
Ex-smoker 124,960 33.4 121,530 33.4 3,430 34.4
Missing 95,882 25.6 93,219 25.6 2,663 26.7
Maternal BMI (kg/m2)
Normal (18.5–24.9) 160,544 42.9 156,382 42.9 4,162 41.7
Underweight (,18.5) 30,384 8.1 29,597 8.1 787 7.9
Overweight (25–29.9) 59,267 15.8 57,693 15.8 1,574 15.8
Obese (.= 30) 32,132 8.6 31,209 8.6 923 9.2
Missing 91,869 24.6 89,333 24.5 2,536 25.4
MCAs =major congenital anomalies; BMI = body mass index.
doi:10.1371/journal.pone.0100996.t001
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Sensitivity analyses
We conducted three sensitivity analyses to ensure the robustness
of the study results. Firstly, we restricted the group of children
whose mothers were prescribed benzodiazepines or non-benzodi-
azepine hypnotics to those of mothers with monotherapy only and
compared the risks of overall MCA and the three most prevalent
system-specific groups to the risks in children of mothers without
depression or anxiety. Secondly, we repeated the main analysis
after restricting the drug-exposed groups to those children born to
women with at least one high-dose prescription. The high-dose
prescription was defined as 15 mg or above per day for diazepam,
20 mg or above per day for temazepam, and 7.5 mg or above per
day for zopiclone. Thirdly, we repeated the main analysis after
restricting the drug-exposed groups to those children born to
women with at least two prescriptions for the same individual
drug. All analyses were carried out using Stata SE 11.0 (Stata
Corp., College Station, TX, USA).
Power calculation
Based on the study population we used for the purpose of this
study, we estimated that we had over 90% power to detect an OR
of 2.0 for the association of MCA overall with antenatal exposure
to un-medicated depression/anxiety or with exposure to diazepam
in the first trimester at 1% significance level (99% CIs). We had in
contrast 60% power to detect a similar effect for temazepam and
zopiclone. However, when we changed the significance level to
5% (95% CIs), we had nearly 80% power to detect a similar effect
for temazepam and zopiclone. This power calculation was
performed using G*Power 3.1 [40].
Results
Of 374,196 live-born singletons, 2.7% (99%CI 2.6–2.7%) had
major congenital anomalies. The median maternal age at birth
was 29 years (interquartile range 25–33). Children with MCAs had
similar maternal characteristics to children without MCAs
(Table 1). There were 19,193 (5.1%) children born to women
with diagnosed depression or anxiety but with no first trimester
medication and 3,218 (0.9%) with first trimester exposure to
anxiolytic or hypnotic drugs, of which 1,175 children (36.5%) had
concurrent exposure to antidepressants (65.5% of which were
SSRIs). Women prescribed anxiolytic/hypnotic drugs were more
likely to be from socioeconomically deprived groups than women
with depression/anxiety un-medicated in early pregnancy
(Table 2).
The prevalence of MCA was similar across all exposure groups:
2.7% (99%CI 2.6-.27%) in the baseline group of children whose
mothers were not diagnosed with depression or anxiety, 2.7%
(2.4–3.0%) in those whose mothers had diagnosed depression or
anxiety un-medicated in the first trimester, 2.7% (1.6–4.1%) in
children exposed to diazepam without antidepressants in the first
trimester, 2.9% (1.1–5.9%) in children exposed to temazepam
without antidepressants, 2.5% (0.9–5.2%) in children exposed to
zopiclone without antidepressants (Table 3) and 3.4% (0.9–8.8%)
in children exposed to other anxiolytic/hypnotic drugs without
antidepressants. Compared with the baseline group, adjusted ORs
were 1.02 (99%CI 0.63–1.64) for diazepam, 1.07 (0.49–2.37) for
temazepam, 0.96 (0.42–2.20) for zopiclone (Table 4) and 1.27
(0.43–3.75) for other anxiolytic/hypnotic drugs when not concur-
rently prescribed an antidepressant. When assessing the MCA risk
for exposure to benzodiazepines and non-benzodiazepines con-
current with antidepressants, the adjusted ORs were 1.07 (0.53–
2.17) for diazepam, 1.13 (0.41–3.07) for temazepam, 1.44 (0.72–T
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2.91) for zopiclone (Table 4) and 1.35 (0.45–4.03) for other
anxiolytic/hypnotic drugs.
Absolute risks of system-specific congenital anomalies showed
small variations across different exposure groups with both
increases and decreases and no specific rise for children with
drug exposures (Table 3). Congenital heart anomaly was the most
common system-specific anomaly with an absolute risk prevalence
of 0.8% in children born to women both with and without
depression/anxiety, ranging from 0.9–1.7% in children of mothers
prescribed diazepam, temazepam, zopiclone or other anxiolytic/
hypnotic drugs without antidepressants in early pregnancy
(Table 3). None of the AOR provided evidence for statistically
significant differences between the exposure groups (Table 4). The
absolute risks of limb and genital system anomalies were similar in
children of women with and without early antenatal drug
exposures (Table 3). In adjusted analyses, 99%CIs all included
the null for congenital anomalies of the limbs and genital systems
(Table 4).
Results from using children born to women with un-
medicated illness as the baseline group
Similar results were found when using children of mothers with
diagnosed anxiety or depression but without any drug exposure in
the first trimester as the baseline group (Table 5) and the adjusted
ORs were 0.99 (99%CI 0.61–1.61) for diazepam, 1.04 (0.47–2.32)
for temazepam, 0.93 (0.40–2.15) for zopiclone and 1.25 (0.42–
3.68) for other anxiolytic/hypnotic drugs.
Results from sensitivity analyses
Table 6 shows the results from the three sensitivity analyses.
After restricting our analysis to children of mothers with
monotherapy only, we found almost identical results to the main
analysis. There were only 379 children born to women prescribed
high-dose diazepam in the first trimester, 117 for temazepam and
241 for zopiclone. Similarly, there were very few children of
mothers with at least two prescriptions for the same individual
drug (214 for diazepam, 55 for temazepam and 73 for zopiclone).
Although the power was inevitably reduced for the latter two
analyses, we found similar effect measurements to the main
analysis and all 99%CIs were overlapping.
Discussion
Principal Findings
We did not find that early antenatal prescriptions of diazepam,
temazepam, zopiclone, or other anxiolytic/hypnotic drugs were
associated with excess risks of MCA overall or with system-specific
groups. The overall MCA risk was similar in children whose
mothers had and had not co-prescriptions of antidepressants in the
first trimester. The estimates remained almost unchanged when
using children born to women with diagnosed depression or
anxiety but without anxiolytic, hypnotic or antidepressant
exposures as the comparison group.
Strength and Limitations
Our study is among only a few to have estimated the risks of
overall MCA and system-specific anomalies in children exposed to
benzodiazepine drugs and non-benzodiazepine hypnotics exclud-
ing women who may have also been exposed to antidepressants in
the first trimester of pregnancy. The exposure, outcome and
covariate data were from UK general practices and recorded
prospectively in the course of routine clinical care, thus excluding
recall bias. Since there are a large number of comparisons in our
study, we used 99%CIs to minimise the potential risk of false
positive results due to multiple testing. We also adjusted for year of
childbirth, maternal age at childbirth, smoking, BMI and
socioeconomic status to minimise potential confounding effects
from these factors.
MCA prevalence estimates across all system-specific groups and
specific MCA diagnoses in the general practice database we have
used have been compared with those reported in UK registers of
the European Surveillance of Congenital Anomalies network, and
were shown to be highly complete and specific [26]. We included
MCAs diagnosed up to age 20 years where available, so we expect
to have captured these outcomes as completely as registry data if
not more so [26]. As stillbirths are recorded in the mother’s
record, but stillborn children do not have their own registration in
the primary care database, we only included live-born children, as
has been the case in most previous studies of congenital anomaly
risk. Since stillbirth overall occurs in less than 1% of all births [41]
and only 8–14% of stillbirths are believed to be due to congenital
abnormalities [42,43], the effect of excluding stillbirths on our risk
estimates will be minimal.
Table 5. Association between benzodiazepine prescribing in the first trimester of pregnancy and the risk of major congenital
anomalies in offspringa.
Diazepamb Temazepamb Zopicloneb
n=1,159 n=379 n=406
AOR 99%CI AOR 99%CI AOR 99%CI
Any MCAs 0.99 0.61–1.61 1.04 0.47–2.32 0.93 0.40–2.15
Heart 1.29 0.60–2.80 1.31 0.35–4.92 2.03 0.69–6.02
Limb 1.42 0.47–4.31 — 0.64 0.05–8.49
Genital system 0.57 0.12–2.60 — —
aChildren born to women with depression or anxiety but without anxiolytic, hypnotic or antidepressant drugs in the first trimester as the comparison group & gaps in
the table indicated insufficient data available for the specific comparisons.
bDoes not include children born to women with co-prescriptions of antidepressants in the first trimester of pregnancy.
AOR= odds ratio adjusted for maternal age at childbirth and calendar year at birth at a categorical variables, body mass index and maternal smoking and socioeconomic
status.
MCAs =major congenital anomalies; CI = confidence interval.
doi:10.1371/journal.pone.0100996.t005
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In the UK, general practice has a gate-keeping role and is the
first point of contact for non-emergency access to almost all
national health care services. Moreover, all pregnant women in the
UK are required to be registered with a general practitioner in
order to benefit from antenatal care and free prescriptions. It is
therefore unlikely that we did not identify women with prescrip-
tions for the psychotropic drugs assessed. However, there could be
potential misclassification in the exposure if a woman receiving a
drug prescription did not actually take the medication or did not
take it during the organogenesis period, which could bias our
estimates towards a null finding. All population-based studies large
enough to assess MCA risks are limited in their ability to obtain
women’s actual medication consumption and self-reported use has
not been shown to be more reliable.
Potential confounding by indication is a limitation of all
observational studies of drug safety. Because benzodiazepines are
prescribed for a range of indications we excluded children whose
mothers had been diagnosed with severe mental illness or epilepsy
as these may have introduced important confounding. Temaze-
pam and zopiclone are primarily indicated for insomnia which is
often associated with anxiety, and diazepam is also commonly
prescribed for anxiety. In this population of pregnant women, we
believe that these will account for the vast majority of indications
for such prescriptions. Hyperemesis gravidarum is rarely treated
with diazepam in the UK and this occurs among only 0.5–2% of
pregnant women [44]. Our findings that risks were similar when
compared to women in the general population and women with
diagnosed but un-medicated depression or anxiety are reassuring.
The prevalence of diagnosed maternal depression and anxiety in
UK primary care has been previously measured and shows similar
estimates to survey studies using clinical diagnostic criteria [33].
Interpretation in context of previous studies
Very few population-based studies have examined the potential
teratogenic effects of individual benzodiazepines or non-benzodi-
azepine hypnotic drugs [8]. Two matched case-control studies
using a large population-based database from the Hungarian
Case-Control Surveillance of Congenital Abnormalities generally
found no increased risks of congenital anomalies overall in
children born to women treated with diazepam in early pregnancy
[45,46] apart from some small increases of specific anomalies such
as congenital limb anomalies. The information on antenatal
exposure however was partly collected through women’s self-
report after childbirth which is inevitably subjected to recall bias.
Although a considerable proportion of women on such
medications are also prescribed other psychotropic medications
such as antidepressants previous research generally has investigat-
ed the teratogenic effects of anxiolytic and hypnotic drugs without
assessing concurrent medication use. A population-based study
using the Swedish Medical Birth Register [10] found a 37%
increased risk of MCA in children with early antenatal exposure to
any benzodiazepines (OR=1.37, 95%CI 1.07–1.76), but not to
non-benzodiazepine hypnotics (OR=1.09, 95%CI 0.68–1.75)
after adjusting for some maternal factors. The authors found
increases of alimentary tract atresia and pyloric stenosis (risk ratios
(RR) = 2.63 and 3.80, 95%CIs 1.01–5.42 and 1.53–7.84) in
children exposed to any benzodiazepines or non-benzodiazepine
hypnotics in early pregnancy. However, 31% of women exposed
to benzodiazepine anxiolytics or non-benzodiazepine hypnotics
were also prescribed antidepressants and the authors noted that
some of their benzodiazepine-exposed congenital anomaly cases
were also exposed to antidepressants or anticonvulsive drugs in
early pregnancy. A later study conducted by the same author [12]
also found no association of maternal use of non-benzodiazepine
hypnotics with relatively severe congenital anomalies overall
(RR=1.02, 95%CI 0.75–1.38) except for a five-fold increase of
intestinal abnormalities other than atresia/stenosis (RR=5.06,
95%CI 1.38–13.0). Neither of the studies however excluded use of
antidepressants or anticonvulsants from their analyses.
Oberlander and colleagues, using population-based registry
data from British Columbia, Canada in 2008 [11] did assess both
sole- and co-prescribing and found that antenatal exposure to
benzodiazepines combined with antidepressants, but not benzo-
diazepines alone, were associated with a higher risk of congenital
heart anomalies (risk difference = 1.18, 95%CI 0.18–2.18 for dual
exposure and 20.13, 20.55–0.29 for sole exposure). This
Canadian study [11] however did not assess the potential
contribution of underlying illnesses. It is possible that women
with both antidepressant and benzodiazepine medications have
more severe mental illness. Although we were unable to separate
the drug effect from the underlying mental illness, we found
similar effect measurements when comparing the risks of
congenital anomalies in children with different anxiolytic and
hypnotic drug exposures to children of mothers with depression or
anxiety but without such drug treatment. In addition, since there is
an increasing interest in the potential teratogenic effect of
antidepressants in both research and medical practice settings, it
is possible that children with dual exposure to specific antidepres-
sants may be more likely to be assessed and subsequently
diagnosed with congenital anomalies at earlier age than children
of healthy mothers.
Conclusions
This first UK population-based study found no evidence of
increased risks of MCAs associated with antenatal drug exposure
to diazepam, temazepam, zopiclone or other anxiolytic/hypnotic
drugs. Our results indicate that prescription of these drugs during
early pregnancy may be safe in terms of MCA risk, but findings
from other studies are required before safety can be confirmed.
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